BioTech
Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being